FULC on XNAS, Health Care, Fulcrum Therapeutics, Inc., job postings
Measures activity, not value. Not investment advice.
Shares fell 67% in 12 months as losses reached $76.3M, while cash stands at $116.4M.
WatchShort interest 8.4% of shares, down 4.7% on the prior report
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $10.9M.
31 Dec 2021RevenueNet incomeNet losstallest bar $80.0M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$10.9M
30 Jun 2026
–
-$26.2M
31 Mar 2026
–
-$18.9M
31 Dec 2025
$0
-$20.3M
30 Sep 2025
$0
-$19.6M
30 Jun 2025
$0
-$17.3M
31 Mar 2025
–
-$17.7M
31 Dec 2024
$0
-$16.6M
30 Sep 2024
$0
-$21.7M
30 Jun 2024
$80.0M
$55.4M
31 Mar 2024
$0
-$26.9M
31 Dec 2023
$871K
-$24.8M
30 Sep 2023
$759K
-$24.0M
30 Jun 2023
$880K
-$23.8M
31 Mar 2023
$295K
-$24.8M
31 Dec 2022
$685K
-$26.1M
30 Sep 2022
$1.2M
-$23.7M
30 Jun 2022
$1.9M
-$34.1M
31 Mar 2022
$2.6M
-$25.9M
31 Dec 2021
$5.1M
-$23.5M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$76.3M
-$71.1M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$1.04
-$1.14
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-30.5%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$116.4M
$47.1M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$116.4M (net cash)
-$47.1M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$3.95
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.93
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-2.6%
149 13F filers vs 153
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
78.4M shares held by 13F filers (30 Sep 2026) of 76.4M outstanding (8 Nov 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
8.4%
6.4M shares sold short (30 Oct 2026) of 76.4M outstanding (8 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
4.8
6.4M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-4.7%
6.8M shares sold short in the report before, 6.4M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
68%
68% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 44%
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$150K
4 quarters
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
11
11 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
11×
11 articles in the last 7 days; its usual week has 1.
Price $3.69 on 20 Nov 2026, -67% over 12 months (12-month range $3.14 to $14.60)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $57.3M in the last 12 months (the 12 months before: -$168K).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months.Revenue per quarter. Revenue $0 in the latest quarter.Capital spending per quarter. Capital spending $108K in the latest quarter, +66% on a year earlier.Institutional holders (13F filers). 149 13F filers reported holding it in the latest 13F quarter, +22% on a year earlier.Lobbying spend. Lobbying spend: $150K published in the last 12 months, +25% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $5.1M, +20% on a year earlier; public on 4 Mar 2022
Quarter ended 31 Mar 2022: $2.6M, -46% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $1.9M, -57% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $1.2M, -76% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $685K, -86% on a year earlier; public on 10 Mar 2023
Quarter ended 31 Mar 2023: $295K, -89% on a year earlier; public on 16 May 2023
Quarter ended 30 Jun 2023: $880K, -53% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $759K, -36% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $871K, +27% on a year earlier; public on 28 Feb 2024
Quarter ended 31 Mar 2024: $0, -100% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $80.0M, +8991% on a year earlier; public on 1 Aug 2024
Quarter ended 30 Sep 2024: $0, -100% on a year earlier; public on 14 Nov 2024
Quarter ended 31 Dec 2024: $0, -100% on a year earlier; public on 26 Feb 2025
Quarter ended 30 Jun 2025: $0, -100% on a year earlier; public on 30 Jul 2025
Quarter ended 30 Sep 2025: $0; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $0; public on 25 Feb 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $519K, +10% on a year earlier; public on 4 Mar 2022
Quarter ended 31 Mar 2022: $246K, -6.1% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $1.3M, +133% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $283K, -23% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $116K, -78% on a year earlier; public on 10 Mar 2023
Quarter ended 31 Mar 2023: $171K, -30% on a year earlier; public on 16 May 2023
Quarter ended 30 Jun 2023: $195K, -85% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $65K, -77% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $77K, -34% on a year earlier; public on 28 Feb 2024
Quarter ended 31 Mar 2024: $28K, -84% on a year earlier; public on 14 May 2024
Quarter ended 30 Sep 2024: $19K, -71% on a year earlier; public on 14 Nov 2024
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $65K; public on 30 Jul 2025
Quarter ended 30 Sep 2025: $90K, +374% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $159K; public on 25 Feb 2026
Quarter ended 31 Mar 2026: $8K; public on 28 Apr 2026
Quarter ended 30 Jun 2026: $108K, +66% on a year earlier; public on 31 Jul 2026
Institutional holders (13F filers)
31 Dec 2021 report: 100; public on 14 Feb 2022
31 Mar 2022 report: 102; public on 16 May 2022
30 Jun 2022 report: 96; public on 15 Aug 2022
30 Sep 2022 report: 101; public on 14 Nov 2022
31 Dec 2022 report: 106; public on 14 Feb 2023
31 Mar 2023 report: 112; public on 15 May 2023
30 Jun 2023 report: 85; public on 14 Aug 2023
30 Sep 2023 report: 77; public on 14 Nov 2023
31 Dec 2023 report: 99; public on 14 Feb 2024
31 Mar 2024 report: 124; public on 15 May 2024
30 Jun 2024 report: 116; public on 14 Aug 2024
30 Sep 2024 report: 125; public on 14 Nov 2024
31 Dec 2024 report: 118; public on 14 Feb 2025
31 Mar 2025 report: 113; public on 15 May 2025
30 Jun 2025 report: 119; public on 14 Aug 2025
30 Sep 2025 report: 122; public on 14 Nov 2025
31 Dec 2025 report: 167; public on 17 Feb 2026
31 Mar 2026 report: 162; public on 15 May 2026
30 Jun 2026 report: 153; public on 14 Aug 2026
30 Sep 2026 report: 149; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Oct 2022: $20K published
Quarter from 1 Jan 2023: $30K published
Quarter from 1 Apr 2023: $30K published
Quarter from 1 Jul 2023: $30K published
Quarter from 1 Oct 2023: $30K published
Quarter from 1 Jan 2024: $30K published
Quarter from 1 Apr 2024: $30K published
Quarter from 1 Jul 2024: $60K published
Quarter from 1 Oct 2024: $60K published
Quarter from 1 Apr 2025: $40K published
Quarter from 1 Jul 2025: $40K published
Quarter from 1 Oct 2025: $40K published
Quarter from 1 Jan 2026: $40K published
Quarter from 1 Apr 2026: $50K published
Quarter from 1 Jul 2026: $60K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $595K (20 Jul 2026), higher than 88% of its own history.
In 12 months: 4 director or officer changes, 2 major agreements, 1 agreement ended, 1 restructuring. Results releases and routine reports are left out.
Filed
What happened
Source
17 Aug 2026
Director or officer change; Signed a major agreementSame filing: sold shares privately, change of control
Reported lobbying spend: $60K in Q2 2026, $50K in Q1 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
30 Jun 2026
Ended
The Mcmanus Groupfor Fulcrum Therapeutics
Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025.Health issues
Two or more unrelated kinds of records unusual within 30 days
30 Jul 2024confirmed
Confirmed across sources Filings + Financials and Lobbying and Short interest and volume
Fulcrum Therapeutics(FULC): lobbying on a new issue; it also reported revenue of $80.0M for the quarter ended 30 Jun 2024, 91× the same quarter last year; and it had 11.4M shares sold short in the 13 Sep 2024 report, 3.0× the same report last year. Three unrelated kinds of activity within 74 days.
Lobbying: Lobbying on a new issue, became public on 19 Jul 2024
Short interest and volume: Short interest spike, became public on 25 Jul 2024
Financials: Quarterly revenue change, became public on 6 Aug 2024
Short interest and volume: Short interest spike, became public on 10 Aug 2024
Short interest and volume: Short interest spike, became public on 27 Aug 2024
Short interest and volume: Short interest spike, became public on 12 Sep 2024
Short interest and volume: Short interest spike, became public on 25 Sep 2024
The quarter ended 30 Jun 2024 against the 8 quarters before it.
this quarterearliernormal: $815KSee the evidence (7 changes)
Lobbying: Lobbying on a new issue became public on 19 Jul 2024
Fulcrum Therapeutics lobbying on a new issue.
New
['PHA']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
6409906
Short interest and volume: Short interest spike became public on 25 Jul 2024
Fulcrum Therapeutics had 7.3M shares sold short in the 15 Jul 2024 report, 2.1× the same report last year.
This period
7.3M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
3.5M
Typical spread (median absolute deviation)
360K
How far from its usual level
+7.0
Same report last year
3.5M
History used
1,811 days
the 15 Jul 2024 report24 earlier reportsnormal: 3.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 6 Aug 2024
Fulcrum Therapeutics reported revenue of $80.0M for the quarter ended 30 Jun 2024, 91× the same quarter last year.
This period
$80.0M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$815K
Typical spread (median absolute deviation)
$249K
How far from its usual level
+79.2
Same quarter last year
$880K
History used
1,552 days
the quarter ended 30 Jun 20248 earlier quartersnormal: $815K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 10 Aug 2024
Fulcrum Therapeutics had 7.7M shares sold short in the 31 Jul 2024 report, 2.2× the same report last year.
This period
7.7M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
379K
How far from its usual level
+7.3
Same report last year
3.5M
History used
1,827 days
the 31 Jul 2024 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Aug 2024
Fulcrum Therapeutics had 8.2M shares sold short in the 15 Aug 2024 report, 3.0× the same report last year.
This period
8.2M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
411K
How far from its usual level
+7.4
Same report last year
2.7M
History used
1,842 days
the 15 Aug 2024 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Sep 2024
Fulcrum Therapeutics had 8.1M shares sold short in the 30 Aug 2024 report, 2.3× the same report last year.
This period
8.1M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
365K
How far from its usual level
+8.1
Same report last year
3.6M
History used
1,857 days
the 30 Aug 2024 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Sep 2024
Fulcrum Therapeutics had 11.4M shares sold short in the 13 Sep 2024 report, 3.0× the same report last year.
This period
11.4M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
448K
How far from its usual level
+11.5
Same report last year
3.7M
History used
1,871 days
the 13 Sep 2024 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
15 Feb 2022confirmed
Confirmed across sources Institutional holdings and Short interest and volume
Fulcrum Therapeutics(FULC): saw 26 13F filers open a new position in the quarter ended 31 Dec 2021, 2.2× the same quarter last year, while it had 2.6M shares sold short in the 15 Feb 2022 report, 3.6× the same report last year. Two unrelated kinds of activity within 28 days.
Short interest and volume: Short interest spike, became public on 27 Jan 2022
Institutional holdings: Many funds opening a new position, became public on 14 Feb 2022
Short interest and volume: Short interest spike, became public on 10 Feb 2022
Short interest and volume: Short interest spike, became public on 26 Feb 2022
The quarter ended 31 Dec 2021 against the 8 quarters before it.
this quarterearliernormal: 10.5See the evidence (4 changes)
Short interest and volume: Short interest spike became public on 27 Jan 2022
Fulcrum Therapeutics had 1.8M shares sold short in the 14 Jan 2022 report, 2.0× the same report last year.
This period
1.8M (the 14 Jan 2022 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
128K
How far from its usual level
+5.1
Same report last year
905K
History used
898 days
the 14 Jan 2022 report24 earlier reportsnormal: 813K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 14 Feb 2022
Fulcrum Therapeutics saw 26 13F filers open a new position in the quarter ended 31 Dec 2021, 2.2× the same quarter last year.
This period
26 (the quarter ended 31 Dec 2021)
Normal quarter (median of 8 earlier)
10.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+4.2
Same quarter last year
12
History used
823 days
the quarter ended 31 Dec 20218 earlier quartersnormal: 10.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 10 Feb 2022
Fulcrum Therapeutics had 2.1M shares sold short in the 31 Jan 2022 report, 3.0× the same report last year.
This period
2.1M (the 31 Jan 2022 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
128K
How far from its usual level
+6.8
Same report last year
708K
History used
915 days
the 31 Jan 2022 report24 earlier reportsnormal: 813K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Feb 2022
Fulcrum Therapeutics had 2.6M shares sold short in the 15 Feb 2022 report, 3.6× the same report last year.
This period
2.6M (the 15 Feb 2022 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
143K
How far from its usual level
+8.7
Same report last year
724K
History used
930 days
the 15 Feb 2022 report24 earlier reportsnormal: 813K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
16 Nov 2021confirmed
Confirmed across sources Institutional holdings and Short interest and volume
Fulcrum Therapeutics(FULC): saw 38 13F filers open a new position in the quarter ended 30 Sep 2021, 5.4× the same quarter last year, while it had 3.0M shares sold short in the 15 Nov 2021 report, 2.9× the same report last year. Two unrelated kinds of activity within 70 days.
Short interest and volume: Short interest spike, became public on 13 Oct 2021
Short interest and volume: Short interest spike, became public on 27 Oct 2021
Institutional holdings: Many funds opening a new position, became public on 15 Nov 2021
Short interest and volume: Short interest spike, became public on 10 Nov 2021
Short interest and volume: Short interest spike, became public on 25 Nov 2021
Short interest and volume: Short interest spike, became public on 10 Dec 2021
Short interest and volume: Short interest spike, became public on 28 Dec 2021
The quarter ended 30 Sep 2021 against the 8 quarters before it.
this quarterearliernormal: 10.5See the evidence (7 changes)
Short interest and volume: Short interest spike became public on 13 Oct 2021
Fulcrum Therapeutics had 2.1M shares sold short in the 30 Sep 2021 report, 1.8× the same report last year.
This period
2.1M (the 30 Sep 2021 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
118K
How far from its usual level
+7.2
Same report last year
1.1M
History used
792 days
the 30 Sep 2021 report24 earlier reportsnormal: 813K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Oct 2021
Fulcrum Therapeutics had 2.1M shares sold short in the 15 Oct 2021 report, 1.7× the same report last year.
This period
2.1M (the 15 Oct 2021 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
118K
How far from its usual level
+7.2
Same report last year
1.2M
History used
807 days
the 15 Oct 2021 report24 earlier reportsnormal: 813K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 Nov 2021
Fulcrum Therapeutics saw 38 13F filers open a new position in the quarter ended 30 Sep 2021, 5.4× the same quarter last year.
This period
38 (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
10.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+7.4
Same quarter last year
7
History used
731 days
the quarter ended 30 Sep 20218 earlier quartersnormal: 10.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 10 Nov 2021
Fulcrum Therapeutics had 2.1M shares sold short in the 29 Oct 2021 report, 1.6× the same report last year.
This period
2.1M (the 29 Oct 2021 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
118K
How far from its usual level
+7.2
Same report last year
1.3M
History used
821 days
the 29 Oct 2021 report24 earlier reportsnormal: 813K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Nov 2021
Fulcrum Therapeutics had 3.0M shares sold short in the 15 Nov 2021 report, 2.9× the same report last year.
This period
3.0M (the 15 Nov 2021 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
118K
How far from its usual level
+12.7
Same report last year
1.0M
History used
838 days
the 15 Nov 2021 report24 earlier reportsnormal: 813K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Dec 2021
Fulcrum Therapeutics had 2.1M shares sold short in the 30 Nov 2021 report, 2.2× the same report last year.
This period
2.1M (the 30 Nov 2021 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
118K
How far from its usual level
+7.3
Same report last year
931K
History used
853 days
the 30 Nov 2021 report24 earlier reportsnormal: 813K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Dec 2021
Fulcrum Therapeutics had 1.7M shares sold short in the 15 Dec 2021 report, 1.9× the same report last year.
This period
1.7M (the 15 Dec 2021 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
120K
How far from its usual level
+5.0
Same report last year
884K
History used
868 days
the 15 Dec 2021 report24 earlier reportsnormal: 813K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
had 8.0M shares sold short in the 30 Apr 2026 report, 2.3× the same report last year.
Same report last year: 3.4M; its normal report is 3.8M.
See the evidence
This period
8.0M (the 30 Apr 2026 report)
Normal report (median of 24 earlier)
3.8M
Typical spread (median absolute deviation)
530K
How far from its usual level
+5.3
Same report last year
3.4M
History used
2,465 days
the 30 Apr 2026 report24 earlier reportsnormal: 3.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.6M shares sold short in the 15 Apr 2026 report, 2.1× the same report last year.
Same report last year: 3.6M; its normal report is 3.8M.
See the evidence
This period
7.6M (the 15 Apr 2026 report)
Normal report (median of 24 earlier)
3.8M
Typical spread (median absolute deviation)
431K
How far from its usual level
+5.9
Same report last year
3.6M
History used
2,450 days
the 15 Apr 2026 report24 earlier reportsnormal: 3.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.0M shares sold short in the 31 Mar 2026 report, 1.9× the same report last year.
Same report last year: 3.7M; its normal report is 3.7M.
See the evidence
This period
7.0M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
351K
How far from its usual level
+6.2
Same report last year
3.7M
History used
2,435 days
the 31 Mar 2026 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 54 13F filers open a new position in the quarter ended 31 Dec 2025, 2.8× the same quarter last year.
Same quarter last year: 19; its normal quarter is 23.
See the evidence
This period
54 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
23
Typical spread (median absolute deviation)
4
How far from its usual level
+5.2
Same quarter last year
19
History used
2,284 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 23
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 11.4M shares sold short in the 13 Sep 2024 report, 3.0× the same report last year.
Same report last year: 3.7M; its normal report is 3.7M.
See the evidence
This period
11.4M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
448K
How far from its usual level
+11.5
Same report last year
3.7M
History used
1,871 days
the 13 Sep 2024 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.1M shares sold short in the 30 Aug 2024 report, 2.3× the same report last year.
Same report last year: 3.6M; its normal report is 3.7M.
See the evidence
This period
8.1M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
365K
How far from its usual level
+8.1
Same report last year
3.6M
History used
1,857 days
the 30 Aug 2024 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.2M shares sold short in the 15 Aug 2024 report, 3.0× the same report last year.
Same report last year: 2.7M; its normal report is 3.6M.
See the evidence
This period
8.2M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
411K
How far from its usual level
+7.4
Same report last year
2.7M
History used
1,842 days
the 15 Aug 2024 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.7M shares sold short in the 31 Jul 2024 report, 2.2× the same report last year.
Same report last year: 3.5M; its normal report is 3.6M.
See the evidence
This period
7.7M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
379K
How far from its usual level
+7.3
Same report last year
3.5M
History used
1,827 days
the 31 Jul 2024 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $80.0M for the quarter ended 30 Jun 2024, 91× the same quarter last year.
Same quarter last year: $880K; its normal quarter is $815K.
See the evidence
This period
$80.0M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$815K
Typical spread (median absolute deviation)
$249K
How far from its usual level
+79.2
Same quarter last year
$880K
History used
1,552 days
the quarter ended 30 Jun 20248 earlier quartersnormal: $815K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
lobbying on a new issue; it also reported revenue of $80.0M for the quarter ended 30 Jun 2024, 91× the same quarter last year; and it had 11.4M shares sold short in the 13 Sep 2024 report, 3.0× the same report last year. Three unrelated kinds of activity within 74 days.
See the evidence (7 changes)
Lobbying: Lobbying on a new issue became public on 19 Jul 2024
Fulcrum Therapeutics lobbying on a new issue.
New
['PHA']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
6409906
Short interest and volume: Short interest spike became public on 25 Jul 2024
Fulcrum Therapeutics had 7.3M shares sold short in the 15 Jul 2024 report, 2.1× the same report last year.
This period
7.3M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
3.5M
Typical spread (median absolute deviation)
360K
How far from its usual level
+7.0
Same report last year
3.5M
History used
1,811 days
the 15 Jul 2024 report24 earlier reportsnormal: 3.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 6 Aug 2024
Fulcrum Therapeutics reported revenue of $80.0M for the quarter ended 30 Jun 2024, 91× the same quarter last year.
This period
$80.0M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$815K
Typical spread (median absolute deviation)
$249K
How far from its usual level
+79.2
Same quarter last year
$880K
History used
1,552 days
the quarter ended 30 Jun 20248 earlier quartersnormal: $815K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 10 Aug 2024
Fulcrum Therapeutics had 7.7M shares sold short in the 31 Jul 2024 report, 2.2× the same report last year.
This period
7.7M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
379K
How far from its usual level
+7.3
Same report last year
3.5M
History used
1,827 days
the 31 Jul 2024 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Aug 2024
Fulcrum Therapeutics had 8.2M shares sold short in the 15 Aug 2024 report, 3.0× the same report last year.
This period
8.2M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
411K
How far from its usual level
+7.4
Same report last year
2.7M
History used
1,842 days
the 15 Aug 2024 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Sep 2024
Fulcrum Therapeutics had 8.1M shares sold short in the 30 Aug 2024 report, 2.3× the same report last year.
This period
8.1M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
365K
How far from its usual level
+8.1
Same report last year
3.6M
History used
1,857 days
the 30 Aug 2024 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Sep 2024
Fulcrum Therapeutics had 11.4M shares sold short in the 13 Sep 2024 report, 3.0× the same report last year.
This period
11.4M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
448K
How far from its usual level
+11.5
Same report last year
3.7M
History used
1,871 days
the 13 Sep 2024 report24 earlier reportsnormal: 3.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
25 Jul 2024Short interest and volume change
had 7.3M shares sold short in the 15 Jul 2024 report, 2.1× the same report last year.
Same report last year: 3.5M; its normal report is 3.5M.
See the evidence
This period
7.3M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
3.5M
Typical spread (median absolute deviation)
360K
How far from its usual level
+7.0
Same report last year
3.5M
History used
1,811 days
the 15 Jul 2024 report24 earlier reportsnormal: 3.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.1M shares sold short in the 14 Apr 2023 report, 1.9× the same report last year.
Same report last year: 2.7M; its normal report is 3.5M.
See the evidence
This period
5.1M (the 14 Apr 2023 report)
Normal report (median of 24 earlier)
3.5M
Typical spread (median absolute deviation)
207K
How far from its usual level
+4.5
Same report last year
2.7M
History used
1,353 days
the 14 Apr 2023 report24 earlier reportsnormal: 3.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.9M shares sold short in the 31 Mar 2023 report, 1.8× the same report last year.
Same report last year: 2.7M; its normal report is 3.5M.
See the evidence
This period
4.9M (the 31 Mar 2023 report)
Normal report (median of 24 earlier)
3.5M
Typical spread (median absolute deviation)
217K
How far from its usual level
+4.1
Same report last year
2.7M
History used
1,339 days
the 31 Mar 2023 report24 earlier reportsnormal: 3.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 100 entries; narrow the window or the kind of data to see older ones.
Not listed: 147 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001680581
Ticker
FULC
Domain
fulcrumtx.com
Employer name
FULCRUM THERAPEUTICS INC. (1 unverified)
Hq location
MA|CAMBRIDGE|02139 (1 unverified)
Lobbying client
fulcrum therapeutics
Name
Fulcrum Therapeutics, Inc.
Wikidata
Q104481162
DOL H-1B labor condition applications and PERM certifications42 data points10 Feb 2020 to 3 Apr 2023
Federal lobbying disclosures (LDA)4 records, 47 data points1 Sep 2022 to 30 Jun 2026
SEC Form 13F institutional holdings261 data points30 Sep 2019 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)134 records25 Jul 2016 to 12 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)476 data points31 Dec 2017 to 8 Nov 2026
SEC Form 4 insider transactions68 records, 208 data points22 Jul 2019 to 20 Jul 2026
FINRA short interest (twice monthly)521 data points31 Jul 2019 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)3696 data points18 Jul 2019 to 20 Nov 2026